Top 8 Covid Vaccines & Their Types

Basic Introduction to Covid 19 Vaccine

Scientists from all over the globe continue their race against time by developing new generations’ vaccinations as we speak–these scientists work tirelessly day after endless day until cures may finally become reality once more.

The world is working to develop a vaccine for COVID-19, with 21 different vaccines currently being rolled out in countries around the globe. Scientists hope that one day they can prevent this deadly pandemic from ever happening again by preventing more people than ever before from getting sick.

A recent article explores all of these new developments and which candidate has been most effective so far!

Recent Updates About Covid Vaccines

There are 121 COVID-19 vaccine candidates undergoing clinical trials and 194 in pre-clinical development. One Canadian company, Medicago found their phase 3 trial for a new product; while another from India has successfully completed it too! A third Turkish firm had registered its newly developed TURKOVAC as well which is going through the first two phases of evaluation with promising results so far.

Main Types Of Coronavirus Vaccines

The names and famous types of coronavirus vaccines are given below for the sake of providing benefits to the user of this article.

#Name of Coronavirus VaccineType of Covid Vaccine
Major Covid 19 vaccines and their types


What do you know about Moderna USA Vaccine? The type of Moderna vaccine is RNA VACCINE.

Moderna is a company that makes vaccines. The Moderna Vaccine was created in Cambridge, Massachusetts by researchers at the National Institute for Allergy and Infectious Diseases (NIAID). They are funded by NIAID to test it out on volunteers from Kaiser Permanente Washington Health Research Institute.

The Moderna vaccine is also known as Spikevax or mRNA-1273. It was developed in the USA by a company called “Moderna,” which is located outside of Boston at Cambridge Innovation Center (CIC), Massachusetts, and funded through NIH’s National Institute for Allergy & Infectious Diseases (NIAID). The NIAID administers it to patients who have not previously been vaccinated against influenza A/H1NIOS with two doses four weeks apart; then they run clinical trials on volunteers ranging from 18 years old up to 75+. This particular phase 1+2 trials were completed back in 2016

The first vaccine against the deadly pandemic was approved by Danish officials in February and is now available for adults 18 years old. The US Food & Drug Administration (FDA) has authorized its use as well – with some restrictions on children between 12-17 who have yet to develop an immunity due to their age at the time of infection or vaccination last year; they are allowed only one dose per person regardless if there are multiple recipients in a household until 2022 when this restriction will be lifted.

A phase 2 trial began taking place August 2021 where scientists gave transplants failing two doses another chance after seeing response rates increase among patients previously vaccinated once before.

The vaccine is currently in phase 4 trials. It has been authorized for use by Danish authorities, and will soon be available to those under 18 years old if they need it clinically as well! As an emergency therapy with no side effects or risks of disease transmission, this could prove useful when outbreaks occur because vaccines have often failed at preventing infections before due time periods (10-14 days). With luck and enough data from the trial process, we should know more about its effectiveness within a few months though – stay tuned!!


What do you know about the AstraZeneca vaccine? AstraZeneca vaccine type is VIRAL VECTOR VACCINE.

AstraZeneca has developed a vaccine that can be easily transported and administered in two doses. The AstraZeneca vaccine was granted emergency use authorization by the European Medicines Agency, WHO as well as national regulators worldwide. It is fridge stable meaning it’s easy to take anywhere–at about US$ 4 per dose for lower-income nations, this makes vaccines available at affordable prices even more so than others on offer! In phase 3 clinical trials with over 10 thousand people from across the UK including children & older adults tested its effectiveness against meningitis C virus strain MU Duc89m

AstraZeneca’s vaccine is a life-saving and cost-effective option for countries with lower incomes. It can be easily transported anywhere in the world at only 4 dollars per dose; this makes them accessible to those who need it most financially disadvantaged populations like children or older people living on limited budgets unable to afford other vaccines

In 2021, the University of Oxford registered a new phase 1 trial in which they are investigating how to administer the ChAdOx1 vaccine by nasal spray. This differs from their current intramuscular injection process for delivering this nationally- rollout shot that has been shown effective at prevention and transmission but poses some safety concerns related mainly to comfortenance (ability to breath).

By adapting delivery methods on 27 June 2018 as part given volunteers who were healthy yet vaccinated before entering into it — so-called “passive immunization”– researchers hope we can find out whether such changes result in enhanced protection especially against mild disease or not.

Important guide about PFIZER/BIONTECH (GERMANY)

The Pfizer Biotech type is RNA VACCINE.

In 2020, the UK became the first country in Europe to approve this new vaccine designed for use among people who are immune-compromised or have cancer. It is now being used worldwide and has been given emergency status by WHO as well! BioNTech worked with Pfizer on its development before launching global human trials where they initially tested it out on 300 patients from Germany only; then expanded into the United States of America too–starting at Memorial Sloan Kettering Cancer Center (MSKCC) last year.

It is now being used worldwide and has even received emergency use listing from WHO for its ability to prevent future outbreaks like Ebola or Marburg virus disease which had been threatening public health all over Africa as well other continents including Europe ever since 2014 when they were last seen there until recently.

BioN tech, working together with Pfizer started testing this new type on humans starting out only within Germany but then it was later expanded globally via trials conducted mostly abroad across America too because at least three countries needed clinical data before approval could happen–America being one such place

 A vaccine has been approved for kidney transplant recipients in the US. The new, more potent immunization is now available to anyone 16 and older who needs it—a first of its kind!

This life-saving treatment was given emergency approval by federal agencies on 23 August 2021 when we reached full phase 2 activation status; meaning patients can get vaccinated without any hesitation due solely based upon their age or health condition they are being treated as an urgent need case rather than just preventive medicine like before where you have had time since making application

Important things to know about SINOVAC (CHINA)


Sinovac trials in China have shown promising results, and the company is now conducting phase 3 studies with higher doses of vaccine for longer periods. In July 2021 reports stated that Sinova’s emergency approval was extended due to its safe use on high-risk groups like health workers who work in areas affected by diseases such as SARS or the H1N1 flu pandemic.

The company started phase 4 trials back in February 2021 after conducting three successful phase 3 clinical studies involving volunteers from Brazil, Turkey &Indonesia. A single dose was shown effective against infection with both culture-confirmed(by PCR)and suspect isolates obtainedfromHong Kong hospital infections (2017), Ohio respiratory syncytial virus(2018).

A trial began this past February looking at safety & immunogenicity when giving booster shots after 2 months has passed since receiving the initial course of treatment–the Phase II Study Design also involved close follow up over 6 weeks where adverse events were monitored closely while monitoring if recipients had sufficient immunity levels against given disease proteins through vaccination

Useful points about CANSINO BIOLOGICS INC. (CHINA) Vaccine

Cansino by China is VIRAL VECTOR VACCINE.

The Ad5-nCoV vaccine candidate uses a harmless non-replicating viral vector to carry vaccine antigens into the human body – this is the same platform that CanSino Biologics Inc., based in Tianjin, used for its Ebola trial. COVID 19 was jointly developed by The Institute of Biotechnology (IOTB)of Academy Military Medical Sciences (AMMS). On 25th June 2020, it received approval from China’s military which makes them eligible as “special needed drugs” within their borders meaning they can be distributed and prescribed without needing further testing or certification. In August 2020, after getting the final nod from the Ministry Of Health Saudi Arabia announced plans on running trials using test subjects who have been previously diagnosed.

In May 2021, the company registered a phase 4 trial with 300 adult participants who have been primed to inoculate them against SARS-CoV. On 5 August 2021, Reuters reported that antibody levels in people vaccinated could drop down around 30%.

Beijing Institute Of Biological Products

The vaccine developed by BBIBP is INACTIVATED VACCINE.

The Beijing Institute is part of China’s state-run Sinopharm Group and developed a vaccine called BBIBP CorV in collaboration with the Chinese Center for Disease Control. The group has launched phase 4 trials to assess safety, immunogenicity, and efficacy that began October 2021; it will examine two doses followed by adults 18 years old or older getting boosters afterward every other year as well.

The trial took place at no cost with 5,000 people receiving this new life-saving immunization across UAE borders before their scheduled dateline; between November 2021 – January 2022!



Scientists at J&J have developed a vaccine for the Ebola virus. They are currently in phase 1/2 trials with plans to make 500 million doses of this new, preventative medication available worldwide by 2021 and hope that it will be effective against other highly contagious diseases as well such as SARS or MERS-CoV ( coronavirus ). In addition, they’re giving high hopes on their latest innovation: recombinant adenovirus type 26 which has largely helped curb cases seen since its introduction back in 2000!

MODERNA/National Institute Of Allergies And Infectious Diseases (US)

The type of this Moderna vaccine is RNA VACCINE.

Moderna’s mRNA-1273 has been approved and is currently being used for SARS treatment in the US, but they are now working on a vaccine that targets this new CoV variant. The trial will test their second COVID-19 drug candidate with NIAID funding to see if it provides protection against Beta variants like SAARTO did before its deletion from circulation during phase I testing last year when we first identified these mutations which make them more dangerous than other strains of coronavirus Bothersome symptoms can include severe respiratory infection (including pneumonia), eyesight problems caused by inflammation within one’s pupils; difficulty breathing or even death without early intervention!

The mRNA-1273.351 vaccine candidate will specifically target the SARS-CoV-2 Beta variant, which was first identified in South Africa and then subsequently spread around the world due to its El Tor strain of causation for disease outbreak control efforts–the COVID program’s goal since its inception through 2020 with an emphasis on2018). This time though Moderna has gone one step further: after testing their successful second phase 1 trial overall success rate at 25% (both vaccinated AND nonvaccinated) by coadministering both together as planned before administering only sequentially or alone; now they’re seeking your feedback about whether you prefer them altered so that future vaccinations can

In 2021, a phase 2 trial to test the efficacy of an HPV vaccine in cancer patients was launched with 120 participants. In June, Moderna simultaneously began testing mRNA-1273 351 for COVID -19 prevention among adolescents between 12 and 17 years old. On 11 August 2021, it emerged that this younger age bracket is also appropriate when considering how quickly new cases increase later into life; results from another study on adults demonstrate boosters can enhance immune response after immunization as well!

The United States Food and Drug Administration has authorized the use of a booster shot in transplant recipients to ensure that they are fully vaccinated. A phase 4 trial was registered on 1 September 2021, which will study how well this vaccination works for kidney transplant patients who did not seroconvert after two doses at an earlier stage than planned.

After a kidney transplant, it is possible that the recipient will not have sero-converted and thus be weakened. This means they may need an additional booster shot so as not to risk infection or other complications during their recovery process from surgery

The United States Food and Drug Administration has authorized the use of vaccine boosters in this situation where there haven’t been any reactions after two doses on September 2021 when studied efficacy; phase 4 trial registration was made one day ago!

Important note about this post:

The information presented here by Lawgranny does not constitute medical advice but simply my take on what I read; please research independently before using this info yourself!

Leave a Comment